

New Cancer Report: “Emerging Cancer Therapies – Markets and Opportunities”

This Report not only describes recent developments in the therapy of cancer, it also serves as a benchmarking tool as well as a useful guide to partner identification. This report also acts as a sales forecast system with current and future potential sales projected for many major product groups.

Contents:

1. Epidemiology

- Incidence
- Prevalence
- Deaths
- Current Therapy

2. Companies and Products in Clinical Trials and in Pre-Clinical Development

3. Small Molecules

- Antibiotics and Anthracyclines
- DNA and RNA Replication Inhibitors including alkylating agents
- DNA and RNA synthesis inhibitors and anti-metabolites, including suicide gene therapy
- Topoisomerase I and Topoisomerase II inhibitors
- Cell structure modulators and anti-mitosis agents including inhibitors of beta-tubulin polymerization and depolymerization
- Hormone-based products for hormone sensitive breast cancer and hormone sensitive prostate cancer
- Agents that modulate signal pathways and agents focusing on promotion of apoptosis
- Angiogenesis and metastasis inhibitors
- Telomerase Inhibitors
- Histone deacetylase inhibition
- Miscellaneous small molecules (photodynamic therapy, inhibitors of mitochondrial oxidation-reduction, sterol inhibition, vitamin D derivatives, etc.)

4. Biological Products

- Monoclonal antibodies, immuno-conjugates combining monoclonal antibodies with toxins, cytotoxic drugs and radionuclides
- Vaccines and immune system stimulants including vaccine adjuvants
- Cytokines, including gene therapy
- Modified viruses and bacteria

5. Aspects Covered in Each Section

- Recent approvals and launches
- Mechanisms-of-Action
- Summary of indications for each drug in clinical trial
- Competitive analysis
- Sales 2001 – 2010 (in sections where this is feasible)
- Proposed scenario of product launches 2002 to 2007

6. Collaborations at Early Drug Discovery Stages

- Genomics
- Proteomics
- Chemical Libraries
- High-throughput screening
- Co-development of new concepts

About the Author – Dr. Brian Minter

Before starting his own consultancy in 1991, Dr. Brian Minter worked as a research biochemist at Pfizer, as scientific editor for *Biochemica Biophysica Acta* (Elsevier Science Publications) both located in The Netherlands, as marketing manager of fine chemical intermediates for drug active production at DSM Andeno and Solvay Duphar, and in drug registration/medical devices for Solvay Pharmaceuticals. He has prepared and presented a number of workshops on emerging cancer therapies and is the author of many related publications.